Imagion Biosystems has lodged the announcement “Pro-Rata Non-Renounceable Rights Issue” with the Australian Securities Exchange.
View the announcement “Pro-Rata Non-Renounceable Rights Issue.”
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal